Long-Term Treatment With Imidapril but Not With Nifedipine Enhances Plasma NOx Concentration in Patients With Essential Hypertension

• Suda Osamu

  Second Department of Internal Medicine, University of Occupational and Environmental Health, Japan Health Care Center, Central Japan Railway Company, Japan

• Tsutsui Masato

  Department of Pharmacology, School of Medicine, University of Occupational and Environmental Health, Japan Department of Cardiology, Moji Rousai Hospital, Japan

• Morishita Tsuyoshi

  Second Department of Internal Medicine, University of Occupational and Environmental Health, Japan

• Horiuchi Masataka

  Second Department of Internal Medicine, University of Occupational and Environmental Health, Japan

• Nakata Sei

  Second Department of Internal Medicine, University of Occupational and Environmental Health, Japan

• Kouzuma Ryouji

  Second Department of Internal Medicine, University of Occupational and Environmental Health, Japan

• Okazaki Masahiro

  Second Department of Internal Medicine, University of Occupational and Environmental Health, Japan

• Sumiyama-Fujinishi Akiko

  Department of Cardiology, Moji Rousai Hospital, Japan

• Mizuki Tsunetaka

  Department of Cardiology, Moji Rousai Hospital, Japan

• Yanagihara Nobuyuki

  Department of Pharmacology, School of Medicine, University of Occupational and Environmental Health, Japan

• Tasaki Hiromi

  Second Department of Internal Medicine, University of Occupational and Environmental Health, Japan

• Nakashima Yasuhide

  Second Department of Internal Medicine, University of Occupational and Environmental Health, Japan

抄録

We investigated whether long-term treatment with the angiotensin-converting enzyme (ACE) inhibitor imidapril or the calcium channel antagonist nifedipine increases systemic nitric oxide (NO) production in patients with essential hypertension. Twenty-nine patients with essential hypertension were randomly divided into two groups, and they were treated with either imidapril or nifedipine once daily p.o. for 4 weeks. Long-term treatment with imidapril significantly decreased blood pressure and increased plasma NOx concentration. Long-term treatment with nifedipine also caused a comparable extent of significant decrease in blood pressure, but failed to alter plasma NOx levels. The imidapril treatment significantly inhibited serum ACE activity and increased plasma bradykinin concentration. Furthermore, the extent of inhibition of serum ACE activity and the extent of increase in plasma bradykinin concentration in response to the imidapril treatment were both significantly correlated with the extent of increase in plasma NOx concentration. In contrast, no such changes were noted after the nifedipine treatment. These results provide the first evidence that long-term treatment with imidapril enhances plasma NOx concentration in patients with essential hypertension. This effect does not seem to be due to the decrease in blood pressure. The increase in bradykinin concentration may be involved in the enhancing effect of the ACE inhibitor on NOx production in vivo.<br>

収録刊行物

• Journal of Pharmacological Sciences

  Journal of Pharmacological Sciences 101 (2), 159-165, 2006

  公益社団法人 日本薬理学会

キーワード

• angiotensin-converting enzyme inhibitor
• calcium channel antagonist
• human
• hypertension
• nitric oxide

詳細情報

• CRID: 1390001205176156928
• NII論文ID: 10018237838
• NII書誌ID: AA11806667
• DOI: 10.1254/jphs.fp0060031
• ISSN: 13478648
• ISSN: 13478613
• NDL書誌ID: 7963365
• Web Site: https://ndlsearch.ndl.go.jp/books/R000000004-I7963365
• Web Site: https://search.jamas.or.jp/link/ui/2007116282
• 本文言語コード: en
• データソース種別:
  • JaLC
  • NDL
  • Crossref
  • CiNii Articles
  • KAKEN
• 抄録ライセンスフラグ: 使用不可